IBISWorld Platform
Answer any industry question in minutes with our entire database at your fingertips.
Genetic Signatures is a Public Company that generates the majority of its income from the Scientific Research Services industry. In 2025 the company generated total revenue of $21,364,000 including sales and other revenue. The exact number of employees for this organisation is not available. The Chief Executive of Genetic Signatures is Dr John Melki whose official title is Managing Director & Chief Executive Officer. The Chairman of Genetic Signatures is Dr Nickolaos Samaras whose official title is Non-Executive Chairman. Genetic Signatures Limited is an ASX-listed company within the biotechnology industry, operating in the USA, Europe, and Australia. The Company's range of products aid in the identification and diagnosis of infectious diseases, such as: gastrointestinal infections sexual health meningitis respiratory anti-microbial resistance tropical diseaseThe Company also provides Sample Processing Kits for 3base conversion and nucleic acid extraction and purification as well as General Purpose Reagents for laboratory use.
Answer any industry question in minutes with our entire database at your fingertips.
Feed trusted, human-driven industry intelligence straight into your platform.
Streamline your workflow with IBISWorld’s intelligence built into your toolkit.
IBISWorld's research coverage on the Genetic Signatures Limited includes market sizing, forecasting, data and analysis. The most recent publication will be as current as of March 2026.
Genetic Signatures Limited, trading as Genetic Signatures, operates under the ABN 30 095 913 205 and was incorporated on 15 February 2001. Genetic Signatures Limited trades on the Australian Securities Exchange under the ticker code ASX:GSS. Genetic Signatures Limited primarily operates in the Scientific Research Services industry in Australia.
The Key Personnel chapter outlines the principal leadership positions within Genetic Signatures Limited, including the Chairman, Board members, Chief Executive Officer, and other key management personnel. It provides an overview of the company’s governance and executive structure, along with a breakdown of gender diversity across leadership roles, offering insight into the composition of the organisation’s senior team.
The Financials chapter presents Genetic Signatures Limited’s historical financial performance, including detailed profit and loss statements outlining sales revenue, cost of sales, and profitability. It also incorporates balance sheet data, providing a breakdown of assets and liabilities, as well as additional financial metrics such as the number of shares on issue. Together, these disclosures offer a comprehensive view of the company’s financial position and performance over time.
The Growth & Ratios chapter provides historical data on key financial performance indicators, enabling an assessment of the company’s operational efficiency, profitability, and financial structure over time. Metrics covered include return on equity, return on assets, profit margins, revenue per employee, as well as gearing and leverage ratios, offering a comprehensive view of performance trends and capital management.
The Operating Segments chapter provides an overview of the revenue composition and asset allocation across the various industries in which Genetic Signatures Limited operates. It offers insights into how the company’s financial performance is distributed among its core business segments, highlighting the relative contribution of each industry to total revenue.
The Competitor Benchmarking chapter includes a comparative assessment of Genetic Signatures Limited’s key financial, growth, and valuation ratios against industry averages to evaluate its competitive position. It analyses valuation metrics such as price-to-earnings, price-to-book, enterprise value to EBITDA, and enterprise value to sales, alongside core financial indicators including liquidity ratios and profitability measures.
The Shareholders chapter provides a breakdown of the ownership structure of Genetic Signatures Limited, identifying key shareholders and outlining their respective ownership interests. This section offers insight into the concentration of shareholdings, the presence of institutional or strategic investors, and the overall distribution of equity within the company.
The Subsidiaries chapter provides an overview of the companies and business entities that are wholly or partially owned by Genetic Signatures Limited. It outlines the ownership structure of each subsidiary, offering insight into the broader corporate group and how these entities contribute to the company’s overall activities and performance.
The History chapter presents a overview of Genetic Signatures Limited’s development, highlighting key milestones and significant corporate events since its incorporation. It includes the company’s incorporation date and outlines major strategic, operational, and structural developments, providing context for its evolution and current market position.
More than 6,000 businesses use IBISWorld to shape local and global economies
We were able to supplement our reports with IBISWorld’s information from both a qualitative and quantitative standpoint. All of our reporting now features some level of IBISWorld integration.
IBISWorld delivers the crisp business knowledge we need to drive our business. Whether it be serving up our major clients, winning new business or educating on industry issues, IBISWorld brings real value.
IBISWorld has revolutionised business information — which has proved commercially invaluable to exporters, investors and public policy professionals in Australia and overseas.
When you’re able to speak to clients and be knowledgeable about what they do and the state that they operate in, they’re going to trust you a lot more.
Genetic Signatures Limited is an ASX-listed company within the biotechnology industry, operating in the USA, Europe, and Australia. The Company's range of products aid in the identification and diagnosis of infectious diseases, such as: gastrointestinal infections sexual health meningitis respiratory anti-microbial resistance tropical diseaseThe Company also provides Sample Processing Kits for 3base conversion and nucleic acid extraction and purification as well as General Purpose Reagents for laboratory use.
Genetic Signatures Limited, trading as Genetic Signatures, is a Public Company that generates the majority of its income from the Scientific Research Services industry in Australia.
Murray Cod Australia Limited company is based at 7 Eliza Street, Newton, New South Wales, Australia.
The OPERATIONS DECISION MAKER of Genetic Signatures Limited is Mark Langan and the OPERATIONS DECISION MAKER is Doug Millar.
In 2025, Genetic Signatures Limited generated total revenue of approximately $21.4 million.